Corney Sarah M, Dukatz Tamra, Rosenblatt Solomon, Harrison Barbara, Murray Robert, Sakharova Alla, Balasubramaniam Mamtha
Department of Anesthesia, Anesthesia Staffing Consultants, Hillsdale Community Health Center, Hillsdale, Michigan 49242, USA.
J Diabetes Sci Technol. 2012 Sep 1;6(5):1003-15. doi: 10.1177/193229681200600503.
Patients with diabetes who use insulin pumps [continuous subcutaneous insulin infusion (CSII)] undergo surgeries that require postoperative hospital admission. There are no defined guidelines for CSII perioperative use.
This retrospective single-institution study identified type 1 and type 2 diabetes subjects by electronically searching 2005-2010 anesthesia preoperative assessments for "pump." Surgical cases (n = 92) were grouped according to intraoperative insulin delivery method: (a) CSII continuation of basal rate with/without correctional insulin bolus(es) (n = 53); (b) conversion to intravenous insulin infusion (n = 20); and (c) CSII suspension with/without correctional insulin bolus(es) (n = 19). These groups were compared on mean intraoperative blood glucose (BG) and category of most extreme intraoperative BG.
Differences were found on baseline characteristics of diabetes duration (p = .010), anesthesia time (p = .011), proportions receiving general anesthesia (p = .013), and preoperative BG (p = .033). The conversion group had the longest diabetes duration and anesthesia time; it had a higher proportion of general anesthesia recipients and a higher mean preoperative BG than the continuation group. There was no significant difference in mean BG/surgical case between continuation (163.5 ± 58.5 mg/dl), conversion (152.3 ± 28.9 mg/dl), and suspension groups (188.3 ± 44.9 mg/dl; p = .128). The suspension group experienced a greater percentage of cases (84.2%) with one or more intraoperative BG > 179 mg/dl than continuation (45.3%) and conversion (40%) groups Figure 1 groupings (p = .034).
In this limited sample, preliminary findings are consistent with similar intraoperative glycemic control between CSII continuation and CSII conversion to intravenous insulin infusions. Continuous subcutaneous insulin infusion suspension had a greater rate of hyperglycemia. Preoperative differences between insulin delivery groups complicate interpretations of findings.
使用胰岛素泵[持续皮下胰岛素输注(CSII)]的糖尿病患者接受需要术后住院治疗的手术。目前尚无关于CSII围手术期使用的明确指南。
这项回顾性单机构研究通过电子检索2005 - 2010年麻醉术前评估中出现“泵”的记录来确定1型和2型糖尿病患者。手术病例(n = 92)根据术中胰岛素给药方式分组:(a)CSII继续基础输注量并加/不加校正胰岛素推注量(n = 53);(b)转换为静脉胰岛素输注(n = 20);(c)CSII暂停并加/不加校正胰岛素推注量(n = 19)。比较这些组的术中平均血糖(BG)以及最极端术中BG的类别。
在糖尿病病程(p = 0.010)、麻醉时间(p = 0.011)、接受全身麻醉的比例(p = 0.013)和术前BG(p = 0.033)的基线特征方面发现了差异。转换组的糖尿病病程和麻醉时间最长;与继续组相比,其全身麻醉接受者比例更高,术前平均BG也更高。继续组(163.5±58.5mg/dl)、转换组(152.3±28.9mg/dl)和暂停组(188.3±44.9mg/dl;p = 0.128)之间的每个手术病例平均BG无显著差异。与继续组(45.3%)和转换组(40%)相比,暂停组术中出现一次或多次BG > 179mg/dl的病例百分比更高(84.2%)[图1分组(p = 0.034)]。
在这个有限的样本中,初步结果表明CSII继续使用和CSII转换为静脉胰岛素输注在术中血糖控制方面相似。持续皮下胰岛素输注暂停时高血糖发生率更高。胰岛素给药组之间的术前差异使研究结果的解释变得复杂。